![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercebiotech.com/biotech/bms-axes-eisai-adc-pact-3-years-after-paying-650m-would-be-elahere-rival
https://www.reuters.com/business/healthcare-pharmaceuticals/eisai-biogen-launch-alzheimers-drug-leqembi-china-2024-06-28/
https://www.fiercepharma.com/marketing/eisai-your-hi-fi-leqembi-maker-supports-creation-alzheimers-podcast-miniseries
https://www.reuters.com/business/healthcare-pharmaceuticals/eu-drug-regulator-does-not-refer-eisai-biogen-alzheimers-drug-meeting-notes-2024-03-22/
https://investors.biogen.com/news-releases/news-release-details/leqembir-lecanemab-approved-treatment-alzheimers-disease-china
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761269
https://www.prnewswire.com/news-releases/eisai-presents-results-of-post-hoc-analysis-of-eribulin-mesylate-halaven-at-the-european-society-for-medical-oncology-esmo-congress-2022-301621528.html
https://www.asiaone.com/business/eisai-mhlw-grants-orphan-drug-designation-japan-mecobalamin-ultrahigh-dose-formulation